Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X about a paper by Michel Ducreux et al. published in the Journal of Clinical Oncology:
“PRODIGE 29-UCGI 26 (NEOPAN): Phase III Randomized Trial Comparing FOLFIRINOX or Gemcitabine in Locally Advanced PDAC:
mPFS 9.7 vs 7.7 mo
mOS 15.5 vs 15.5 mo
PFS improved, but more toxicity and no OS benefit. Sufficient data to favour the triplet.”
Title: PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet, Pierre Vanelslander, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, Olivier Bouche.
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Arndt Vogel.
